source
- T-Therapeutics secures $133M Series B to advance TCR-CD3 bispecifics with major pharma investorsT-Therapeutics announced a $133 million Series B financing round backed by several of the world’s largest drug developers, including Eli Lilly, Johnson & Johnson, Merck KGaA and Sanofi, along with…
- Rhythm Pharmaceuticals expands LG Chem obesity drug license, total payout up to $855 millionRhythm Pharmaceuticals and LG Chem have revised their licensing agreement for the oral obesity and hyperphagia drug bivamelagon, increasing the total scheduled payments. The new terms raise the po…